Search

Afshin Shafiee

from Oakland, CA
Age ~60
Get Report
Also known as:
Afshin Shaflee, Afshin Shafiee New
Phone and address:
6627 Gunn Dr, Oakland, CA 94611
Related to:
Parissa Heshmati, 59James Holland, 52William Holland, 54James Derdock, 58
Connected to:
Jahan O Shafiee, 41Nima Shafiee, 41Sarah R Shafiee, 37Babak Shafiei, 40Mohammad Shafiei, 61Parisa Shafiei, 30Lawrence L Shafier, 65Jamal Shafii, 65Ahmad Shafik, 36John T Shafik, 37

Afshin Shafiee Phones & Addresses

  • 6627 Gunn Dr, Oakland, CA 94611
  • 125 Maywood Ave, Rochester, NY 14618 (585) 249-0416 (314) 454-3072
  • 111 East Ave, Rochester, NY 14604 (585) 530-3411
  • 200 East Ave, Rochester, NY 14604 (585) 530-3411
  • 200 East Ave #1215, Rochester, NY 14604 (585) 530-3411
  • 111 East Ave #310, Rochester, NY 14604
  • Walnut Creek, CA
  • 4530 Pine St, Saint Louis, MO 63108 (314) 454-3072
  • 660 S Euclid Ave, Saint Louis, MO 63110
  • 96 Euclid Ave, Saint Louis, MO 63119
  • Metairie, LA
  • New Orleans, LA
  • Valley Cottage, NY

Resumes

Resumes

Afshin Shafiee Photo 1

Pharmaceuticals Executive

View page
Position:
Director, Preclinical R&D at InSite Vision, Inc.
Location:
San Francisco Bay Area
Industry:
Pharmaceuticals
Work:
InSite Vision, Inc. since Sep 2011
Director, Preclinical R&D
Bausch & Lomb Nov 2000 - Dec 2009
Principal Scientist
Washington University School of Medicine Jul 1998 - Jul 2000
Postdoctoral Associate
Tulane University School of Medicine Oct 1995 - Jun 1998
Postdoctoral Fellow
Education:
University of Aberdeen 1989 - 1995
Ph.D., Biochemistry, Cell bilogy University of Surrey 1988 - 1989
MSc., Toxicology Nottingham Trent University 1984 - 1988
BSc., Applied Biology
Afshin Shafiee Photo 2

Independent Consultant

View page
Location:
4530 Pine Blvd west, Saint Louis, MO 63108
Industry:
Pharmaceuticals
Work:
Afshin Shafiee Consulting
Independent Consultant
Insite Vision, Inc. Sep 1, 2011 - May 2017
Director, Preclinical R and D
Bausch + Lomb Nov 2000 - Dec 2009
Principal Scientist
Washington University School of Medicine Jul 1998 - Jul 2000
Postdoctoral Associate
Tulane University Oct 1995 - Jun 1998
Postdoctoral Fellow
Education:
University of Aberdeen 1989 - 1995
Doctorates, Doctor of Philosophy, Biochemistry University of Surrey 1988 - 1989
Master of Science, Masters, Toxicology Nottingham Law School 1984 - 1988
Bachelors, Bachelor of Science, Biology
Skills:
Pharmacology
In Vivo
Clinical Development
In Vitro
Cell
R&D
Biotechnology
Ophthalmology
Cro
Pharmaceutics
Cell Culture
Data Analysis
Protocol
Clinical Trials
Toxicology
Protein Chemistry
Regulatory Submissions
Regulatory Requirements

Publications

Us Patents

Rate Controlled Release Of A Pharmaceutical Agent In A Biodegradable Device

View page
US Patent:
20050031669, Feb 10, 2005
Filed:
Jul 8, 2004
Appl. No.:
10/887381
Inventors:
Afshin Shafiee - Rochester NY, US
Joseph Salamone - Fairport NY, US
Dharmendra Jani - Fairport NY, US
Stephen Bartels - Pittsford NY, US
Jay Kunzler - Canandaigua NY, US
Assignee:
Bausch & Lomb Incorporated - Rochester NY
International Classification:
C12N005/02
A61K009/00
US Classification:
424426000
Abstract:
Chemical erosion drug delivery systems are provided that allow sustained release of therapeutic agents within a treated area for a prolonged period of time.

Effect Of Loteprednol Etabonate On Vascular Dysfunction

View page
US Patent:
20070093461, Apr 26, 2007
Filed:
Sep 12, 2006
Appl. No.:
11/519414
Inventors:
Afshin Shafiee - Rochester NY, US
Dharmendra Jani - Fairport NY, US
Stephen Bartels - Pittsford NY, US
International Classification:
A61K 31/573
US Classification:
514179000
Abstract:
This invention relates to the effect of Loteprednol etabonate on vascular dysfunction in the back of the eye. More specifically, this invention relates to methods of modifying a pathogenic angiogenesis in the back of an eye of a patient, the method comprising administering to a patient in need thereof a pathogenic angiogenesis modifying amount of Loteprednol etabonate. Moreover, this invention relates to methods of modifying pathologic vascular permeability manifested as retinal edema. The method compromises administering to a patient an amount of LE sufficient to reduce retinal edema.

Method For Prolonging Activity Of Autodegradable Enzymes

View page
US Patent:
20070134230, Jun 14, 2007
Filed:
Dec 6, 2006
Appl. No.:
11/567338
Inventors:
Dharmendra Jani - Fairport NY, US
Afshin Shafiee - Rochester NY, US
Bruce Pfeffer - Fairport NY, US
Michael Hartzer - Arlington TX, US
International Classification:
A61K 38/48
C12N 9/64
US Classification:
424094630, 435226000
Abstract:
A method for prolonging the activity of an autodegradable enzyme comprises storing the enzyme after manufacture at a pH less than about 5, and reconstituting the acidified enzyme substantially immediately before use with a buffer having a pH in the range from about 6.5 to about 11, wherein the pH remains within 1 pH unit upon adding said the enzyme into the buffer. The method is useful to provide enzyme for wide use, which otherwise would lose activity upon long storage. In one embodiment the method is applicable to provide enzyme for inducing controlled posterior vitreous detachment.

Method For Prolonging Activity Of Autodegradable Enzymes And Compositions Thereof

View page
US Patent:
20070134231, Jun 14, 2007
Filed:
Nov 17, 2006
Appl. No.:
11/601389
Inventors:
Dharmendra Jani - Fairport NY, US
Kai Kwok - Rochester NY, US
Gregory McIntire - Rochester NY, US
Bruce Pfeffer - Fairport NY, US
Afshin Shafiee - Rochester NY, US
Ruiwen Shi - Cupertino CA, US
Srini Venkatesh - Pittsford NY, US
Hongna Wang - Fairport NY, US
Yan Huang - Webster NY, US
Stephen Davio - Fair Port NY, US
International Classification:
A61K 38/48
A61K 31/198
US Classification:
424094640, 514566000
Abstract:
A composition of a long-acting enzyme comprises the enzyme in a formulation comprising a buffer and an additive selected from the group consisting of tranexamic acid, ε-aminocaproic acid, and analogs of L-lysine other than tranexamic acid and ε-aminocaproic acid, combinations thereof, and mixtures thereof. The composition can further comprise another additive selected from the group consisting of L-lysine, L-arginine, L-ornithine (or its pharmaceutically acceptable salts; e.g., L-ornithine hydrochloride), γ-aminobutyric acid, 5-aminovaleric acid, 7-aminoheptanoic acid, glycylglycine, triglycine, N-α-acetyl-L-arginine, betaine, sarcosine, gelatin, HSA, streptokinase, tPA, uPA, non-ionic surfactants, glycerin, D-sorbitol, combinations thereof, and mixtures thereof. A method for prolonging the activity of an autodegradable enzyme comprises storing the enzyme after manufacture at a low pH, and reconstituting the acidified enzyme before use with a solution containing at least one of such additives. The method is useful to provide enzyme for wide use, which otherwise would lose activity upon long storage. In one embodiment the method is applicable to provide enzyme for inducing controlled posterior vitreous detachment.

Delivery System For Antiangiogenic And Antiinflammatory Pharmaceuticals And Method Of Use

View page
US Patent:
20080125377, May 29, 2008
Filed:
Nov 28, 2006
Appl. No.:
11/563719
Inventors:
Stephen P. Bartels - Pittsford NY, US
Tim Tak Lam - Arcadia CA, US
Afshin Shafiee - Rochester NY, US
Yongqing Lin - Rochester NY, US
International Classification:
A61K 31/505
US Classification:
514 23, 514272
Abstract:
Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are formulations which deliver a variety of therapeutic agents, including but not limited to BOL-303213-X, to a subject for an extended period of time. The formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer BOL-303213-X to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration, or wet age-related macular degeneration in a subject. The formulations may comprise BOL-303213-X or other therapeutic agents.

Method For Prolonging Activity Of Autodegradable Enzymes And Compositions Thereof

View page
US Patent:
20100104551, Apr 29, 2010
Filed:
Oct 22, 2009
Appl. No.:
12/603988
Inventors:
Dharmendra M. Jani - Fairport NY, US
Kai Kwok - Rochester NY, US
Gregory L. McIntire - Rochester NY, US
Bruce A. Pfeffer - Fairport NY, US
Afshin Shafiee - Rochester NY, US
Ruiwen Shi - Cupertino CA, US
Srini Venkatesh - Pittsford NY, US
Hongna Wang - Fairport NY, US
Yan Huang - Webster NY, US
Stephen R. Davio - Fairport NY, US
Assignee:
Talecris Biotherapeutics, Inc. - Research Triangle Park NC
International Classification:
A61K 38/48
A61P 27/02
US Classification:
424 9464
Abstract:
A composition of a long-acting enzyme comprises the enzyme in a formulation comprising a buffer and an additive selected from the group consisting of tranexamic acid, ε-aminocaproic acid, and analogs of L-lysine other than tranexamic acid and ε-aminocaproic acid, combinations thereof, and mixtures thereof. The composition can further comprise another additive selected from the group consisting of L-lysine, L-arginine, L-ornithine (or its pharmaceutically acceptable salts; e.g., L-ornithine hydrochloride), γ-aminobutyric acid, 5-aminovaleric acid, 7-aminoheptanoic acid, glycylglycine, triglycine, N-α-acetyl-L-arginine, betaine, sarcosine, gelatin, HSA, streptokinase, tPA, uPA, non-ionic surfactants, glycerin, D-sorbitol, combinations thereof, and mixtures thereof. A method for prolonging the activity of an autodegradable enzyme comprises storing the enzyme after manufacture at a low pH, and reconstituting the acidified enzyme before use with a solution containing at least one of such additives. The method is useful to provide enzyme for wide use, which otherwise would lose activity upon long storage. In one embodiment the method is applicable to provide enzyme for inducing controlled posterior vitreous detachment.

Compositions And Methods For Treating, Reducing, Ameliorating, Alleviating, Or Inhibiting Progression Of, Pathogenic Ocular Neovascularization

View page
US Patent:
20110189174, Aug 4, 2011
Filed:
Jan 20, 2011
Appl. No.:
13/009894
Inventors:
Afshin Shafiee - Rochester NY, US
Keith W. Ward - Ontario NY, US
International Classification:
A61K 31/506
A61K 39/395
C07D 471/04
A61K 31/713
A61P 27/02
A61P 29/00
US Classification:
4241331, 4241581, 514256, 514274, 544322, 514 44 A
Abstract:
A composition for treating, reducing, ameliorating, alleviating, or inhibiting the progression of, pathological ocular neovascularization comprises an integrin or vitronectin receptor antagonist having any one of Formulae I-XI, as defined herein. The composition can further comprise a VEGF inhibitor. Such composition is administered to an ocular environment by a method such as topical application, periocular injection, intravitreal injection, or intravitreal implantation. The composition can be administered alone or in combination with another procedure chosen to enhance the outcome of the treatment.

Rate Controlled Release Of A Pharmaceutical Agent In A Biodegradable Device

View page
US Patent:
20040253293, Dec 16, 2004
Filed:
Jun 16, 2003
Appl. No.:
10/462184
Inventors:
Afshin Shafiee - Rochester NY, US
Joseph Salamone - Fairport NY, US
Dharmendra Jani - Fairport NY, US
Stephen Bartels - Pittsford NY, US
Jay Kunzler - Canandaigua NY, US
International Classification:
A61F002/00
US Classification:
424/426000
Abstract:
Chemical erosion controlled release drug delivery systems are provided that allow controlled release of sustained concentrations of therapeutic agents within a treated area for a prolonged period of time. The favorable solubility characteristics of the chemical erosion controlled release drug delivery systems are controlled through the hydrophobicity and load level of pharmaceutically active agent or drug. Such controlled solubility characteristics allow for manipulation of the drug release rates depending on the particular therapeutic use and the particular needs of the patient.
Control profile
Afshin Shafiee from Oakland, CA, age ~60 Get Report